SIC
SNDX icon

SJS Investment Consulting’s Syndax Pharmaceuticals SNDX Stock Holding History

SJS Investment Consulting’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6K Buy
119
+37
+45% +$769 ﹤0.01% 1665
2026
Q1 		$1.92K Buy
82
+27
+49% +$587 ﹤0.01% 1286
2025
Q4 		$1.16K Buy
+55
New +$960 ﹤0.01% 1256

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
VIG
Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return

SJS Investment Consulting's SNDX Position: Q2 2026 in Review

SJS Investment Consulting increased its Syndax Pharmaceuticals (SNDX) stake by 45% in Q2 2026, buying an estimated $769 and bringing the position to 119 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

SJS Investment Consulting first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • SJS Investment Consulting held 119 shares of Syndax Pharmaceuticals worth $2.6K as of Q2 2026.
  • SJS Investment Consulting bought 37 Syndax Pharmaceuticals shares in Q2 2026, an estimated $769.
  • Syndax Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1665 holding.
  • SJS Investment Consulting first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.